Effect of levetiracetam on epilepsy-related quality of life

Epilepsia

Volumn 41, Issue 7, 2000, Pages 868-874

  Cramer, Joyce A ^a,d   Arrigo, Celestina ^b   Van Hammée, Geneviève ^b   Gauer, Laura J ^b   Cereghino, James J ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UCB PHARMA   (Belgium)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Clinical trial; Levetiracetam; QOLIE 31; Quality of life; Seizures

Indexed keywords

ETIRACETAM; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; EPILEPSY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 0033934199     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.2000.tb00255.x     Document Type: Article

References (13)

1. Penovich P, Cereghino J, Debrabandere L, Gauer L. Levetiracetam: evaluation of efficacy and safety of different dosages in add-on treatment of partial epilepsy. Epilepsia 1998;39(suppl 6): 68.
2. Shorvon S. Levetiracetam in partial epilepsy: results of phase III clinical trials. Eur J Neurol 1998;5(suppl 3):S143.
3. Ben-Menachem E, Fortpied C, Falter U. Evaluation of the efficacy and tolerability of levetiracetam (LEV) monotherapy in epileptic patients with complex partial seizures. Epilepsia (in press).
4. Cramer JA, Fisher R, Ben-Menachem E, French J, Mattson RH. New antiepileptic drugs: a comparison of key clinical trials. Epilepsia 1999;40:590-600.
5. Cramer JA. Quality of life and outcome measures for epilepsy clinical trials. Pharmacy World & Sci 1997;19:227-30.
6. Cramer JA, Perrine K, Devinsky O, Bryant-Comstock L, Meador K, Hermann BP. Development and cross-cultural translation of a 31-item quality of life questionnaire (QOLIE-31). Epilepsia 1998; 39:81-8.
7. Devinsky O, Vickrey BG, Cramer JA, Perrine K, Hermann B, Meador K, Hays RD. Development of the Quality of Life in Epilepsy Inventory. Epilepsia 1995;36:1089-1104.
8. Guyatt GH, Juniper EF, Walter SD, Griffith LE, Goldstein RS. Interpreting treatment effects in randomized trials. Br Med J 1998; 315:690-3.
9. Wiebe S, Derry PA, McLachlan RS. In search of a minimum clinically important change in epilepsy-specific quality of life instrument. Epilepsia 1997;38(suppl 8):83.
10. Wiebe S, Rose K, Derry P, McLachlan R. Outcome assessment in epilepsy: comparative responsiveness of quality of life and psychosocial instruments. Epilepsia 1997;38:430-8.
11. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Controlled Clin Trials 1989;10:407-15.
12. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimum important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994;47:81-7.
13. Redelmeier DA, Guyatt GH, Goldstein RS. Assessing minimal important difference in symptoms: a comparison of two techniques. J Clin Epidemiol 1996;49:1223-4.